NEW YORK--(EON: Enhanced Online News)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Orthofix International N.V. (NASDAQ:OFIX) resulting from allegations that Orthofix may have issued materially misleading business information to the investing public.
“FDA is actively moving to ‘down classify’ BGS from Class III to Class II, allowing cheap competition to flood in, stealing revenues and crushing margins.”
On December 16, 2016, an article published on SeekingAlpha.com revealed that the “FDA is actively moving to ‘down classify’ BGS from Class III to Class II, allowing cheap competition to flood in, stealing revenues and crushing margins.” The article further revealed that “as of October 1st, 2016 (about 10 weeks ago) the FDA just transferred the BGS down classification process to the specific department responsible for handling the down classification (the department of Orthopedics).” On this news, shares of Orthofix fell sharply during intraday trading on December 16, 2016.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Orthofix investors. If you purchased shares of Orthofix, please visit the firm’s website at http://www.rosenlegal.com/cases-1013.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org or email@example.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827